Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of a 6 Month Oral Treatment With the Chymase Inhibitor BAY 1142524 at a Dose of 25 mg BID in Comparison to Placebo on Top of Standard of Care in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease

Trial Profile

A Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of a 6 Month Oral Treatment With the Chymase Inhibitor BAY 1142524 at a Dose of 25 mg BID in Comparison to Placebo on Top of Standard of Care in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2019

At a glance

  • Drugs Fulacimstat (Primary)
  • Indications Diabetic nephropathies; Type 2 diabetes mellitus
  • Focus Biomarker; Therapeutic Use
  • Acronyms CADA DIA
  • Sponsors Bayer
  • Most Recent Events

    • 24 Jan 2019 Planned primary completion date changed from 10 Sep 2019 to 11 Sep 2019.
    • 24 Jan 2019 Status changed from recruiting to active, no longer recruiting.
    • 01 Nov 2018 Planned End Date changed from 15 Aug 2019 to 23 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top